Trastuzumab-Induced Pneumonitis: A Rare but Potential Toxicity in HER2-Positive Breast Cancer Treatment

Strategic Insights -

Researchers at the University Hospital in Netherlands have reported a case of trastuzumab-induced pneumonitis in a female patient with HER2-positive metastatic breast cancer. The patient developed pulmonary infiltrates and pleural effusion dyspnea after several months of trastuzumab treatment, despite having been treated without complications with a combination of docetaxel, trastuzumab, and dexamethasone. The researchers concluded that while a causative association between trastuzumab and the patient's pulmonary syndrome was not proven, the potential for this toxicity should be considered.

Key Takeaways:

  • The patient was diagnosed with HER2-positive metastatic breast cancer and was treated with a combination of docetaxel, trastuzumab, and dexamethasone for six courses.
  • The patient developed pulmonary infiltrates and pleural effusion dyspnea after several months of trastuzumab treatment.
  • Pleural and bronchoalveolar fluid analyses showed eosinophils, which led to a diagnosis of trastuzumab-induced pneumonitis.
  • The researchers excluded malignancy, infection, and cardiomyopathy as causes of dyspnea.
  • Treatment with steroids resulted in gradual clinical improvement and disappearance of infiltrates.
  • The potential for trastuzumab-induced pneumonitis should be considered in patients treated with this medication.
  • The case highlights the importance of monitoring patients for signs of pneumonitis during trastuzumab treatment.

Statistics:

  • 1 case of trastuzumab-induced pneumonitis was reported in a female patient with HER2-positive metastatic breast cancer.
  • The patient had been treated with six courses of docetaxel and trastuzumab plus dexamethasone.
  • The patient experienced pulmonary infiltrates and pleural effusion dyspnea after several months of trastuzumab treatment.
  • Eosinophils were present in the pleural and bronchoalveolar fluid analyses.

Sources:

  • M.J. Pepels and colleagues, University Hospital, Netherlands. Published in Breast Cancer Research and Treatment (Life-threatening interstitial lung disease associated with trastuzumab: case report. Breast Cancer Research and Treatment, 2009;113(3):609-612).
  • Cancer Weekly editors. Reprinted from staff and other reports via NewsRx.com. Copyright 2009.